{"id":"W4310183164","doi":"10.1159/000528272","title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","year":2022,"lang":"en","type":"article","venue":"Liver Cancer","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":76,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Chugai Pharmaceutical; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Sorafenib; Bevacizumab; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Internal medicine; Hazard ratio; Oncology; Liver cancer; Cancer; Phases of clinical research; Gastroenterology; Confidence interval; Chemotherapy; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003825921,0.0003653997,0.00107432,0.0004474192,0.000244396,0.00001326211,0.0002856311,0.00008259781,0.002347971],"category_scores_gemma":[0.00001637357,0.000275624,0.0002254698,0.001710092,0.0001969498,0.0001792714,0.0003113859,0.0003840993,0.000001276758],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007785041,"about_ca_system_score_gemma":0.0007180907,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01198472,"about_ca_topic_score_gemma":0.004500629,"domain_scores_codex":[0.9967691,0.0005260417,0.0006911019,0.0006873324,0.0009025811,0.0004238725],"domain_scores_gemma":[0.9982269,0.0001425774,0.0004171583,0.0007977523,0.0002253859,0.000190227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03474547,0.00315811,0.9471153,0.0001190766,0.002356047,0.000142234,0.01027947,0.0003095561,0.00009696151,0.000006155665,0.00002100883,0.001650632],"study_design_scores_gemma":[0.08565446,0.005347112,0.8871734,0.00006406672,0.006353996,5.242619e-7,0.00298311,0.01082535,0.001066629,7.039721e-7,0.0001913229,0.0003393733],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921583,0.004220078,0.000003869377,0.00002589839,0.0001584482,0.002687794,0.0006410755,0.00002082545,0.00008374594],"genre_scores_gemma":[0.9985758,0.0003034138,0.00001673639,0.00004680453,0.00003336736,0.0005048211,0.0001657326,0.00005238652,0.000300919],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05994194,"threshold_uncertainty_score":0.9999696,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06051174997819984,"score_gpt":0.2949862541609207,"score_spread":0.2344745041827209,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}